Key result
Lower 3D RVEF linked to ~54% greater adverse cardiopulmonary risk per SD compared to TAPSE.
Why the study?
The authors sought to confirm whether three-dimensional echocardiography-derived right ventricular ejection fraction is more strongly associated with adverse cardiopulmonary outcomes than conventional echocardiographic parameters.
Does three-dimensional echocardiography-derived RVEF show a stronger association with adverse cardiopulmonary outcomes compared to conventional echocardiographic parameters in patients with cardiopulmonary diseases?
Meta-Analysis
Does three-dimensional echocardiography-derived RVEF show a stronger association with adverse cardiopulmonary outcomes compared to conventional echocardiographic parameters in patients with cardiopulmonary diseases?
Hazard Ratio: 1.54 (95% CI 1.04–2.28)
p-value: p=.031
Three-dimensional echocardiography-derived RVEF is a stronger predictor of adverse clinical outcomes than conventional right ventricular functional indices, potentially refining risk stratification in cardiopulmonary diseases.
3D RVEF may enhance RV risk stratification; confirms superior outcome association versus TAPSE, FAC, and FWLS.
AIMS: We aimed to confirm that three-dimensional echocardiography-derived right ventricular ejection fraction (RVEF) is better associated with adverse cardiopulmonary outcomes than the conventional echocardiographic parameters. METHODS: We performed a meta-analysis of studies reporting the impact of unit change of RVEF, tricuspid annular plane systolic excursion (TAPSE), fractional area change (FAC), and free-wall longitudinal strain (FWLS) on clinical outcomes (all-cause mortality and/or adverse cardiopulmonary outcomes). Hazard ratios (HRs) were rescaled by the within-study SDs to represent standardized changes. Within each study, we calculated the ratio of HRs related to a 1 SD reduction in RVEF versus TAPSE, or FAC, or FWLS, to quantify the association of RVEF with adverse outcomes relative to the other metrics. These ratios of HRs were pooled using random-effects models. RESULTS: = 65%, P = .002). In studies reporting HRs for RVEF and TAPSE, or RVEF and FAC, or RVEF and FWLS in the same cohort, head-to-head comparison revealed that RVEF showed significantly stronger association with adverse outcomes per SD reduction versus the other 3 parameters (vs TAPSE, HR = 1.54 [95% CI, 1.04-2.28], P = .031; vs FAC, HR = 1.45 [95% CI, 1.15-1.81], P = .001; vs FWLS, HR = 1.44 [95% CI, 1.07-1.95], P = .018). CONCLUSION: Reduction in three-dimensional echocardiography-derived RVEF shows stronger association with adverse clinical outcomes than conventional right ventricular functional indices; therefore, it might further refine the risk stratification of patients with cardiopulmonary diseases.
No takes yet. Share an insight, caveat, or question.
Sayour et al. (2023) conducted a meta-analysis in Cardiopulmonary diseases. Three-dimensional echocardiography-derived right ventricular ejection fraction (RVEF) vs. Conventional echocardiographic parameters (TAPSE, FAC, FWLS) was evaluated on All-cause mortality and/or adverse cardiopulmonary outcomes (HR 1.54, 95% CI 1.04-2.28, p=.031). A 1 SD reduction in 3D echocardiography-derived RVEF had a significantly stronger association with adverse cardiopulmonary outcomes compared to TAPSE (HR 1.54; 95% CI 1.04-2.28; P=0.031).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: